Trials / Completed
CompletedNCT02267629
Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- New York State Psychiatric Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rapastinel (formerly GLYX-13) | 10 mg/kg IV Rapastinel (formerly GLYX-13) |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2014-10-17
- Last updated
- 2017-07-18
- Results posted
- 2017-05-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02267629. Inclusion in this directory is not an endorsement.